Summary
All provided claims concern pricing/access and are not supported by the supplied FDA-approved label excerpts. The only near-label-related claim (“Linzess” as a brand name) is not clearly supported as “linaclotide is a brand drug” by the provided evidence.
Category Scores
Accurate Statements
Linaclotide (brand name Linzess in the US) is a brand drug.
Partially supported: the provided label excerpt references the product name “LINZESS,” but does not explicitly state that “linaclotide is a brand drug” or discuss generic status.
Unsupported Statements
Linaclotide pricing depends on the dose strength and the number of capsules in the package.
The supplied label excerpts do not mention pricing structure or relationships to dose strength/package count.
Linaclotide costs can vary by pharmacy.
No label text in the provided excerpts addresses pharmacy-specific pricing.
Linaclotide costs can vary by insurance coverage.
No label text in the provided excerpts addresses insurance coverage/cost-sharing impacts.
Linaclotide costs can vary depending on whether a discount program is used.
No label text in the provided excerpts mentions discount programs/coupons affecting cost.
Brand linaclotide (Linzess in the US) pricing is typically higher than competitor drugs.
No label text in the provided excerpts compares pricing versus competitor drugs.
Dose and package size (higher strength and larger counts) usually cost more.
No label text in the provided excerpts describes general market pricing rules by strength/count.
Buying through insurance generally results in lower out-of-pocket cost than buying without insurance (cash prices can be much higher).
No label text in the provided excerpts discusses relative out-of-pocket costs for insurance vs cash.
Discounts and pharmacy-specific pricing (coupon cards and negotiated pharmacy rates) can change out-of-pocket cost.
No label text in the provided excerpts addresses coupon cards/negotiated rates/out-of-pocket cost effects.
A cheaper alternative to branded linaclotide may be switching to an available generic or lower-cost competitor product for the same dose/form.
No label text in the provided excerpts provides claims or guidance about cost-based switching to generics/competitors.
Generic availability does not always mean every dose is equally covered by each option.
No label text in the provided excerpts addresses generic availability or dose-by-dose formulary coverage.
Pricing for linaclotide varies by region and pharmacy.
No label text in the provided excerpts addresses regional/pharmacy pricing variability.
Contradictions
Important Omissions
If the user intended dosing/administration/safety guidance, none of the provided claims contain label-supported prescribing information for those topics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The challenged statements are about pricing/access and do not directly claim dosing, contraindications, boxed warnings, or safety actions from the label excerpts provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Pricing/access claims are not present or supported in the supplied FDA-approved label excerpts.
Suggested Improvement
Limit claims to label-supported information (e.g., indications, dosing/administration instructions, contraindications/warnings) and remove or reframe pricing/access statements as non-label content.